Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Burning Rock Biotech Ltd (BNR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BNR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.03
1 Year Target Price $4.03
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 179.34% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.73M USD | Price to earnings Ratio - | 1Y Target Price 4.03 |
Price to earnings Ratio - | 1Y Target Price 4.03 | ||
Volume (30-day avg) 1 | Beta 0.84 | 52 Weeks Range 2.18 - 11.12 | Updated Date 08/29/2025 |
52 Weeks Range 2.18 - 11.12 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -45.59% | Operating Margin (TTM) -11.41% |
Management Effectiveness
Return on Assets (TTM) -14.39% | Return on Equity (TTM) -37.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28435388 | Price to Sales(TTM) 0.18 |
Enterprise Value 28435388 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 0.39 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 9034110 | Shares Floating 48307975 |
Shares Outstanding 9034110 | Shares Floating 48307975 | ||
Percent Insiders 3.92 | Percent Institutions 51.46 |
Upturn AI SWOT
Burning Rock Biotech Ltd
Company Overview
History and Background
Burning Rock Biotech Ltd. was founded in 2014. It focuses on precision oncology, using next-generation sequencing (NGS) technology to guide cancer therapy. Initially focused on research, it transitioned to commercial services and product development.
Core Business Areas
- Central Laboratory Testing Services: Provides comprehensive genomic profiling services to oncologists and hospitals, aiding in treatment decisions and drug selection for cancer patients. Revenue constitutes the largest part of total revenue.
- In Vitro Diagnostic (IVD) Products: Develops and commercializes IVD products based on NGS technology for cancer diagnosis and treatment monitoring.
- Pharmaceutical Services: Provides biomarker analysis and clinical trial support to pharmaceutical companies for drug development. Revenue constitutes the smallest part of total revenue.
Leadership and Structure
The company is led by its founder and CEO. The organizational structure includes departments for research and development, commercial operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- OncoCompass Dx: A pan-cancer companion diagnostic kit. It utilizes NGS to detect actionable genomic alterations in cancer patients, guiding targeted therapy selection. Competitors include Foundation Medicine and Guardant Health. Market share data isn't readily available, but this is a leading revenue source.
- Lung Cancer IVD Products: Developed and commercialized for detection, diagnosis, and treatment monitoring of lung cancer. Competitors include QIAGEN and Roche. Market share data isn't readily available; revenue contribution is less than OncoCompass Dx.
Market Dynamics
Industry Overview
The precision oncology market is growing rapidly, driven by increasing cancer incidence and advancements in NGS technology. Demand for personalized cancer treatments fuels market expansion.
Positioning
Burning Rock Biotechu00a0Ltd is a key player in the Chinese precision oncology market. Its competitive advantage lies in its extensive NGS database and strong relationships with hospitals and oncologists.
Total Addressable Market (TAM)
The global precision oncology market is projected to reach billions of USD. Burning Rock Biotechu00a0Ltd is positioned to capture a significant share of this market, particularly in China, with expansion plans into other regions.
Upturn SWOT Analysis
Strengths
- Strong presence in the Chinese precision oncology market
- Extensive NGS database and bioinformatics capabilities
- Established relationships with hospitals and oncologists
- Strong brand recognition in China
Weaknesses
- Geographic concentration in China
- Dependence on regulatory approvals for IVD products
- Intense competition from international players
- Limited international market presence
Opportunities
- Expanding into new cancer types and diagnostic areas
- Developing novel NGS-based assays and biomarkers
- Forming strategic partnerships with pharmaceutical companies
- Expanding into international markets
Threats
- Regulatory changes and pricing pressures
- Rapid technological advancements and obsolescence
- Increased competition from domestic and international players
- Economic downturn and reduced healthcare spending
Competitors and Market Share
Key Competitors
- FMI
- GH
- ILLM
Competitive Landscape
Burning Rock Biotech faces significant competition from larger, established players like Foundation Medicine and Guardant Health. Its competitive advantage lies in the Chinese market where it has a strong presence.
Growth Trajectory and Initiatives
Historical Growth: Data unavailable without specific financials, historical growth reflected market position and NGS technology.
Future Projections: Future projections are reliant on the growth of precision oncology and its success with IVD products, and adoption of NGS.
Recent Initiatives: Focusing on expanding its IVD product portfolio and partnerships with pharmaceutical companies to boost growth.
Summary
Burning Rock Biotech is positioned as a key player within the Chinese precision oncology market. Its strength is in its local market presence, NGS database, and partnerships. It needs to expand geographically and navigate regulatory hurdles. The company faces threats from intense competition and rapid tech advancements, requiring continuous innovation to maintain its position. Financials needs to improve for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Industry analysis reports
- Market research data
Disclaimers:
The information provided is based on available data and analysis. It is not financial advice, and investment decisions should be made after consulting a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Burning Rock Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-06-12 | Founder, Chairman & CEO Mr. Yusheng Han | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 674 | Website https://www.brbiotech.com |
Full time employees 674 | Website https://www.brbiotech.com | ||
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.